Related references
Note: Only part of the references are listed.Antibodies to watch in 2020
Helene Kaplon et al.
MABS (2020)
A novel method for determining antibody-dependent cellular phagocytosis
Lynn Kamen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies
Michihiko Aoyama et al.
MABS (2019)
Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity
A. Robin Temming et al.
JOURNAL OF IMMUNOLOGY (2019)
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
Matthew Zirui Tay et al.
FRONTIERS IN IMMUNOLOGY (2019)
Design and Production of Bispecific Antibodies
Qiong Wang et al.
ANTIBODIES (2019)
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
Elisabeth A. van Erp et al.
FRONTIERS IN IMMUNOLOGY (2019)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
Antibody glycoengineering strategies in mammalian cells
Qiong Wang et al.
BIOTECHNOLOGY AND BIOENGINEERING (2018)
Identification of Sialic Acid Linkages on Intact Glycopeptides via Differential Chemical Modification Using IntactGIG-HILIC
Shuang Yang et al.
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY (2018)
The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha A. Pereira et al.
MABS (2018)
Simultaneous quantification of N- and O-glycans using a solid-phase method
Shuang Yang et al.
NATURE PROTOCOLS (2017)
Modulating IgG effector function by Fc glycan engineering
Tiezheng Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The Immunoregulatory Roles of Antibody Glycosylation
Madeleine F. Jennewein et al.
TRENDS IN IMMUNOLOGY (2017)
Integrated genome and protein editing swaps α-2,6 sialylation for α-2,3 sialic acid on recombinant antibodies from CHO
Cheng-Yu Chung et al.
BIOTECHNOLOGY JOURNAL (2017)
Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa
Yoshitake Sakae et al.
SCIENTIFIC REPORTS (2017)
Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cells
Cheng-Yu Chung et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines
Yusuke Mimura et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation
Qian Gong et al.
MABS (2016)
Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Marco Thomann et al.
MOLECULAR IMMUNOLOGY (2016)
NK Cells in HIV Disease
Eileen Scully et al.
CURRENT HIV/AIDS REPORTS (2016)
Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation
Bojiao Yin et al.
BIOTECHNOLOGY AND BIOENGINEERING (2015)
Chinese Hamster Ovary (CHO) Host Cell Engineering to Increase Sialylation of Recombinant Therapeutic Proteins by Modulating Sialyltransferase Expression
Nan Lin et al.
BIOTECHNOLOGY PROGRESS (2015)
Fc glycans of therapeutic antibodies as critical quality attributes
Dietmar Reusch et al.
GLYCOBIOLOGY (2015)
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
Isaak Quast et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology
Rinpei Niwa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Production of α2,6-sialylated IgG1 in CHO cells
Celine Raymond et al.
MABS (2015)
A common glycan structure on immunoglobulin G for enhancement of effector functions
Chin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Structural Role of Antibody N-Glycosylation in Receptor Interactions
Ganesh P. Subedi et al.
STRUCTURE (2015)
In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
Marco Thomann et al.
PLOS ONE (2015)
Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities
Masaki Kurogochi et al.
PLOS ONE (2015)
Recent Advances in the Understanding of Biological Implications and Modulation Methodologies of Monoclonal Antibody N-Linked High Mannose Glycans
Helen H. Shi et al.
BIOTECHNOLOGY AND BIOENGINEERING (2014)
Restricted Motion of the Conserved Immunoglobulin G1 N-Glycan Is Essential for Efficient FcγRIIIa Binding
Ganesh P. Subedi et al.
STRUCTURE (2014)
Engineering Hydrophobic Protein-Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies
Xiaojie Yu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
Rebecca J. Rose et al.
MABS (2013)
Antibody-Based Immunotherapy of Cancer
Louis M. Weiner et al.
CELL (2012)
Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines
Ming Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Galactosylation variations in marketed therapeutic antibodies
T. Shantha Raju et al.
MABS (2012)
A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus
Ioscani Jimenez del Val et al.
BIOTECHNOLOGY PROGRESS (2011)
A variant human IgG1-Fc mediates improved ADCC
Ross Stewart et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Enhancement of DNA Uptake in FUT8-Deleted CHO Cells for Transient Production of Afucosylated Antibodies
Athena W. Wong et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
Structure and function of immunoglobulins
Harry W. Schroeder et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Glycosylation as a strategy to improve antibody-based therapeutics
Roy Jefferis
NATURE REVIEWS DRUG DISCOVERY (2009)
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types
Yutaka Kanda et al.
GLYCOBIOLOGY (2007)
Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users
Phinikoula S. Katsamba et al.
ANALYTICAL BIOCHEMISTRY (2006)
Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
MD Pescovitz
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms
C Ferrara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro
J Hodoniczky et al.
BIOTECHNOLOGY PROGRESS (2005)
Establishment of FUT8 knockout Chinese hamster ovary cells:: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
N Yamane-Ohnuki et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Intravenous immunoglobulin and Thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients
E Akalin et al.
TRANSPLANTATION (2003)
The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
T Shinkawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
